Amol Akhade/hiranandanihospital.org
May 24, 2025, 10:01
Amol Akhade Highlights GAIN Trial Results in Resectable BTC at ASCO25
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X:
“BIG BTC Update from ASCO25.
The GAIN trial (Phase III) in resectable BTC (ICC/ECC/GBC) tested:
- Arm A: Perioperative Gem+Cis
- Arm B: Upfront surgery + adjuvant chemo
Here’s what they found: mOS:
- Arm A = 27.8 mo
- Arm B = 14.6 mo
HR 0.46 [0.22–0.96]; p = 0.04 R0 resection rate:
- Arm A = 62.5%
- Arm B = 33.3%
Postop mortality (30-day):
- Arm A = 4.2%
- Arm B = 24%
- No increase in toxicity
- Lower periop deaths
- Higher curative resections
Conclusion: Neoadjuvant Gem+Cis nearly doubled survival and improved surgery outcomes in BTC!
Game-changer for localized disease?”
More posts featuring Amol Akhade on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 24, 2025, 10:01
May 24, 2025, 08:23